Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2005 3
2006 1
2008 2
2009 4
2010 2
2011 5
2012 4
2013 2
2014 1
2015 2
2016 4
2017 1
2018 4
2019 1
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year
Filters applied: . Clear all
Page 1
The p53 story: layers of complexity.
Braithwaite AW, Royds JA, Jackson P. Braithwaite AW, et al. Carcinogenesis. 2005 Jul;26(7):1161-9. doi: 10.1093/carcin/bgi091. Epub 2005 Apr 7. Carcinogenesis. 2005. PMID: 15817608 Review.
YB-1: oncoprotein, prognostic marker and therapeutic target?
Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW. Lasham A, et al. Among authors: braithwaite aw. Biochem J. 2013 Jan 1;449(1):11-23. doi: 10.1042/BJ20121323. Biochem J. 2013. PMID: 23216250 Review.
Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk.
Eiholzer RA, Mehta S, Kazantseva M, Drummond CJ, McKinney C, Young K, Slater D, Morten BC, Avery-Kiejda KA, Lasham A, Fleming N, Morrin HR, Reader K, Royds JA, Landmann M, Petrich S, Reddel R, Huschtscha L, Taha A, Hung NA, Slatter TL, Braithwaite AW. Eiholzer RA, et al. Among authors: braithwaite aw. Cancers (Basel). 2020 Sep 1;12(9):2472. doi: 10.3390/cancers12092472. Cancers (Basel). 2020. PMID: 32882831 Free PMC article.
Dephosphorylation of YB-1 is Required for Nuclear Localisation During G2 Phase of the Cell Cycle.
Mehta S, McKinney C, Algie M, Verma CS, Kannan S, Harfoot R, Bartolec TK, Bhatia P, Fisher AJ, Gould ML, Parker K, Cesare AJ, Cunliffe HE, Cohen SB, Kleffmann T, Braithwaite AW, Woolley AG. Mehta S, et al. Among authors: braithwaite aw. Cancers (Basel). 2020 Jan 29;12(2):315. doi: 10.3390/cancers12020315. Cancers (Basel). 2020. PMID: 32013098 Free PMC article.
Adaptive homeostasis and the p53 isoform network.
Mehta S, Campbell H, Drummond CJ, Li K, Murray K, Slatter T, Bourdon JC, Braithwaite AW. Mehta S, et al. Among authors: braithwaite aw. EMBO Rep. 2021 Nov 15:e53085. doi: 10.15252/embr.202153085. Online ahead of print. EMBO Rep. 2021. PMID: 34779563 Review.
The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.
Kazantseva M, Mehta S, Eiholzer RA, Gimenez G, Bowie S, Campbell H, Reily-Bell AL, Roth I, Ray S, Drummond CJ, Reid G, Joruiz SM, Wiles A, Morrin HR, Reader KL, Hung NA, Baird MA, Slatter TL, Braithwaite AW. Kazantseva M, et al. Among authors: braithwaite aw. Cell Death Dis. 2019 Aug 20;10(9):631. doi: 10.1038/s41419-019-1861-1. Cell Death Dis. 2019. PMID: 31431617 Free PMC article.
Does Δ133p53 isoform trigger inflammation and autoimmunity?
Campbell HG, Slatter TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW. Campbell HG, et al. Among authors: braithwaite aw. Cell Cycle. 2012 Feb 1;11(3):446-50. doi: 10.4161/cc.11.3.19054. Epub 2012 Feb 1. Cell Cycle. 2012. PMID: 22262184
45 results